BABeyza Nur Atay

Beyza Nur Atay

*This is an algorithmically generated author record based on publicly available information.

Beyza Nur Atay has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Bloodstream Infections by Extended-spectrum β-lactamase-producing Klebsiella Species in Children

    by Aysun Yahşi, Emel Arslan, Beyza Nur Atay, Muhammed Yasin Gökdol, Seren Karaciğer, Tuğba Erat, Hatice Kübra Konca, Seval Özen, Bedia Dinç, Gülsüm İcLal Bayhan

    Infections caused by resistant Gram-negative bacteria are a serious public health problem, with Klebsiella spp. being the most common cause and increasing over the years. There is a striking increase in antibiotic resistance worldwide. The aim of this study was to retrospectively evaluate the characteristics and treatment of bloodstream infections (BSIs) caused by Klebsiella spp. and to identify possible risk factors for extended-spectrum β-lactamase (ESBL) resistance in our hospital between August 2019 and March 2023. Of 250 Klebsiella isolates, 112 (44.8%) were ESBL producers and 138 (55.2%) were ESBL nonproducers. Catheter-related BSIs (CRBSIs) accounted for 49.6% of infections and were more common in the ESBL nonproducer group. Most of the Klebsiella spp. were K. pneumoniae (233/250). Most of the infections were healthcare-associated infections (85.6%). Most patients had an underlying disease, the most common underlying disease in the ESBL-producing group was neurometabolic disease (26.8%), whereas in the ESBL-non-producing group it was malignancy (35.5%). The median age of the ESBL-producing group was 14 months and was younger (p=0.01). Previous antibiotic use in the last 30 days, especially aminoglycosides (p<0.006), β-lactam-β-lactamase inhibitor combinations (p<0.001) and cephalosporins (p<0.001), increased ESBL-resistant infection. Use of β-lactam-β-lactamase inhibitor combinations in the last 30 days increased the risk of ESBL resistance by approximately 7.4 times, and cephalosporins increased the risk by 5 times. In the ESBL-producing group, the median duration of treatment was longer at 14 days (p=0.01), and carbapenems were most commonly used (p<0.001). Thrombocytopenia (p=0.003), elevated C-reactive protein (p<0.001), CRBSI (p=0.009), presence of central venous catheter (p=0.03), urinary catheter (p<0.001), mechanical ventilation (p<0.001), intensive care admission (p=0.005), previous use of carbapenems, aminoglycosides, fluoroquinolones in the last 30 days (p=0.003, p=0.001, p=0.006, respectively) and colistin treatment (p<0.001) increased the risk of mortality. The 28-day mortality rate was 11.6%. Appropriate use of narrow-spectrum antibiotics and reduction of invasive procedures is important in reducing ESBL resistance and BSI-related mortality.

  • Open Access

    Characteristics of Klebsiella bloodstream infections and risk factors for carbapenem-resistant Klebsiella infections in children

    by Aysun Yahşi, Gülsüm Iclal Bayhan, Emel Arslan, Muhammed Yasin Gökdöl, Beyza Nur Atay, Seren Karaciğer, Saliha Kanık Yüksek, Belgin Gülhan, Aslınur Özkaya Parlakay

    Objective: Klebsiella spp. is a common and severe pathogen of bloodstream infections (BSI) due to gram-negative bacilli. Carbapenems are commonly used agents for the treatment of serious infections. However, the incidence of carbapenem-resistant (CR) Klebsiella infections has increased significantly in recent years. The aim of this study was to determine the characteristics, risk factors, and outcomes of BSI caused by Klebsiella spp. in a tertiary care pediatric hospital. Method: A retrospective review of pediatric patients with BSI caused by Klebsiella spp. between August 2019 and September 2021 was conducted. Patients with CR isolates were compared with carbapenem-susceptible (CS) isolates for risk factors, outcome, and mortality. Results: Among 345 Klebsiella isolates, 95 (27.5%) were CR. Catheter-related bloodstream infections (CRBSI) accounted for 52.4% of infections. There was an underlying disease in all patients, most commonly malignancy (31.3%). Mechanical ventilation, percutaneous endoscopic gastrostomy (PEG) tube feeding, previous antibiotic use, especially carbapenems, aminoglycosides, glycopeptides, fluoroquinolones, and colistin, (p<0.001, p<0.001, p<0.001, p<0.001, p<0.001, p: 0.033, p<0.001, respectively) were strongly affected the development of BSI due to CR Klebsiella spp. Antibiotic treatment in the previous 14 days increased the risk of developing carbapenem resistance by 14 times. Elevated C-reactive protein (CRP) (p<0.001), thrombocytopenia (p<0.001), CRBSI (p=0.002), use of indwelling devices, previous antibiotic therapy (carbapenems, aminoglycosides, glycopeptides, colistin) (p=0.002), and carbapenem resistance (p=0.001) increased the risk of mortality from Klebsiella-associated BSI. The use of colistin in treatment was higher in the CR group (p<0.001). The 28-day mortality was 15.7%. Conclusion: CR Klebsiella spp. Infections are important and serious causes of BSI in children. The use of indwelling devices and previous antibiotic therapy are risk factors for mortality and carbapenem resistance. Preventive measures, including targeted antimicrobial therapy, good surveillance networks, and less invasive procedures, are important aspects of infection control management in children.